Cryopreserved-thawed Embryo Transfer With or Without Gonadotropin Releasing Hormone Agonist

• Status: Completed
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

Traditionally, the use of GnRH-a suppression was considered essential for adequate endometrial hormonal modulation in cryopreserved-thawed embryo transfer cycles. Several studies, however, have questioned its necessity for controlled endometrial preparation. Using a high dose of estradiol from day 1 of the cycle will suppress the gonadotroph, preventing folliculogenesis and excessive secretion of LH, allowing adequate endometrial preparation without GnRH-a.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Collaborators: Kamal Shaeer center of infertility; Nile Ivf Center, Cairo, Egypt
• Treatments: Deslorelin; Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Polyestradiol phosphate; Progesterone; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• 20-35 years

• BMI 20-30

• Regular menses.

• No PCOS, no endometriosis

• No uterine anomalies or lesions

• No severe male factor

• All grade 1 cleaved stage embryos

Exclusion Criteria:

• Less than 20 or more than 35 years

• BMI less than 20 or more than 30

• Irregular cycles

• PCOS or endometriosis

• Uterine anomalies or lesions

• Severe male factor

• Poor quality embryos for transfer

• Severe